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A B S T R A C T
Aluminum-based adjuvants are the most widely used adjuvants in human vaccines. A comprehensive under-
standing of the mechanism of action of aluminum adjuvants at the molecular level, however, is still elusive.
Here, we unravel the eﬀects of aluminum hydroxide Al(OH)3 by a systems-wide analysis of the Al(OH)3-induced
monocyte response. Cell response analysis by cytokine release was combined with (targeted) transcriptome and
full proteome analysis. Results from this comprehensive study revealed two novel pathways to become activated
upon monocyte stimulation with Al(OH)3: the ﬁrst pathway was IFNβ signaling possibly induced by DAMP
sensing pathways like TLR or NOD1 activation, and second the HLA class I antigen processing and presentation
pathway. Furthermore, known mechanisms of the adjuvant activity of Al(OH)3 were elucidated in more detail
such as inﬂammasome and complement activation, homeostasis and HLA-class II upregulation, possibly related
to increased IFNγ gene expression. Altogether, our study revealed which immunological pathways are activated
upon stimulation of monocytes with Al(OH)3, reﬁning our knowledge on the adjuvant eﬀect of Al(OH)3 in
primary monocytes.
Signiﬁcance: Aluminum salts are the most used adjuvants in human vaccines but a comprehensive understanding
of the working mechanism of alum adjuvants at the molecular level is still elusive. Our Systems Vaccinology
approach, combining complementary molecular biological, immunological and mass spectrometry-based tech-
niques gave a detailed insight in the molecular mechanisms and pathways induced by Al(OH)3 in primary
monocytes. Several novel immunological relevant cellular pathways were identiﬁed: type I interferon secretion
potentially induced by TLR and/or NOD like signaling, the activation of the inﬂammasome and the HLA Class-I
and Class-II antigen presenting pathways induced by IFNγ. This study highlights the mechanisms of the most
commonly used adjuvant in human vaccines by combing proteomics, transcriptomics and cytokine analysis
revealing new potential mechanisms of action for Al(OH)3.
1. Introduction
Since 1926, colloidal aluminum salts are known for their adjuvant
features, when Glenny et al. discovered that diphtheria toxoid adsorbed
to aluminum salts showed a signiﬁcantly higher antibody titer against
the toxoid compared to antigen alone [1]. Since then, aluminum salts
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have been widely used as vaccine adjuvants, even though the me-
chanism of action has remained largely unknown. Shortly after Glenny
et al. discovered its potential, it was observed that the clearance of
aluminum salt-adsorbed toxoids was delayed compared to non-ad-
sorbed toxoids [2]. This observation was the basis for the theory that
antigen‑aluminum salt aggregates form a depot at the site of injection,
leading to a slow release of the bound antigen. However, when the
aluminum salt deposit was removed at various time points, the immune
response was not compromised, suggesting that this is not the only
mechanism by which aluminum salts increase the immune response to
antigens [3]. It was shown that antigens desorb rapidly from AlPO4 as
well as Al(OH)3 after administration, explaining that even when the
aluminum salt-deposit is removed, an antibody response is still created
[4]. It was demonstrated by ﬂow cytometric analysis that Al(OH)3
causes the diﬀerentiation of monocytes to antigen-presenting dendritic
cells, which then can elicit a speciﬁc immune response in the presence
of an antigen [5–7]. Al(OH)3 has been shown to steer the CD4+ T cell
response towards a T helper type 2 (Th2) response and induces the
recruitment of immune cells (e.g. dendritic cells, inﬂammatory mono-
cytes, eosinophils, neutrophils natural killer cells and CD11+ cells) to
the site of injection [7–12].
Additional mechanisms for the adjuvant eﬀect of Al(OH)3 have been
described: for example, the activation of the NLRP3 inﬂammasome, as
identiﬁed by both in vivo and in vitro studies [12–15]. Inﬂammasome
activation results in the secretion of IL-1β, a pro-inﬂammatory cytokine
and potent inducer of the adaptive immune response and Th2 polar-
ization [13, 15, 16]. The inﬂammasome, in vitro, appeared to be critical
for Al(OH)3 dependent IL-1β secretion and antibody responses. In vivo
however, there is conﬂicting data about the necessity of the in-
ﬂammasome to induce a humoral response [13, 15, 17]. Complement
activation is another mechanism involved in the adjuvant activity of Al
(OH)3 [12, 18]. The release of Danger Associated Molecular Patterns
(DAMPs) like uric acid and host DNA, is induced by Al(OH)3 [13, 19,
20]. Uric acid is involved in T cell priming and humoral responses [13,
15]. Besides this, uric acid can also activate the inﬂammasome in vitro
[15, 21]. However, in vivo IL-1β production did not depend on the
presence of uric acid [14, 15]. Uric acid is involved in the inﬂux of
inﬂammatory monocytes to the site of injection as is MyD88, since
MyD88-deﬁcient mice showed a signiﬁcant reduction of the inﬂux of
inﬂammatory monocytes [13]. Even though MyD88 appears to be dis-
pensable for antibody production there is a role in the adjuvant activity
of Al(OH)3 [13]. DNA is also involved in the adjuvant activity of Al
(OH)3 [19]. DNA can result in the secretion of IL-1β or in the secretion
of IFNβ and enhances MHC class II antigen presentation [19, 20]. In
conclusion, there are many potential mechanism described for the ad-
juvant activity of Al(OH)3. A comprehensive study compiling tran-
scriptome data with proteome data would make it possible to follow
pathways in more detail and create an overview of which pathways are
actually activated by the Al(OH)3 adjuvant.
In this study, we investigated the Al(OH)3-induced innate cell re-
sponse at the transcriptome and proteome level, aiming to further
complete the overview of molecular pathways and cellular processes
involved in the adjuvant eﬀect of Al(OH)3. Primary monocytes were
chosen as a model, since these prominent mononuclear phagocytes play
an important role in tissues when activated, bridging the innate and
adaptive immune responses [22, 23]. Besides there known diﬀerentia-
tion into monocyte derived dendritic cells (MDDCs), monocytes can
also enforce their antigen presenting role to T cells in response to
various stimuli as recently reviewed [24]. In the current study the eﬀect
of Al(OH)3 on monocytes will be investigated. The combination of
transcriptome/proteome analyses and cytokine measurements enabled
the comprehensive identiﬁcation of molecular pathways in Al(OH)3-
stimulated monocytes, further clarifying the mechanism by which Al
(OH)3 works.
2. Materials and methods
2.1. Ethics statement
This study was conducted using blood donations, provided by the
National Institute for Public Health and the Environment (Bilthoven,
The Netherlands), for primary cell isolation. The blood donations for
this research goal were speciﬁcally approved by the accredited Medical
Research Ethics Committee (MREC), METC, Noord-Holland in The
Netherlands. The study was conducted according to the principles ex-
pressed in the Declaration of Helsinki and written informed consent was
obtained from all blood donors before collection and use of their
samples. Blood samples were processed anonymously. All human pri-
mary cells described in this study were obtained by the rules of this
ethical statement.
2.2. Reagents used in cell stimulation
Aluminum hydroxide (Alhydrogel 2%; Brenntag; Frederikssund;
Denmark) is referred to as Al(OH)3. Lipopolysaccharide (LPS) from E.
coli K12 (Invivogen; San Diego; California; USA) was used as positive
control and is referred to as LPS.
2.3. Isolation and stimulation of monocytes
Peripheral blood derived from 7 healthy adult donors and obtained
as described in the ethical statement, was used for monocyte isolation.
First, peripheral blood mononuclear cells (PBMCs) were obtained by
gradient centrifugation at 1,000×g for 30min on Lymphoprep
(Nycomed; Zurich; Switzerland). Second, monocytes were isolated from
the PBMC fraction using MACS in combination with anti-CD14 MACS
beads (Miltenyi Biotech; Bergisch Gladbach; Germany). Purity check by
ﬂow cytometric analysis of CD14 cell surface expression was performed
and only if the purity of the monocyte population was ≥95% the cells
were used for proteome and transcriptome analysis.
Monocytes were cultured in a 24-well culture plate (0.6× 106 cells/
ml, 1 ml/well) in RPMI (Gibco/Thermo Fisher; Waltham;
Massachusetts; USA) containing 10% Fetal Calf Serum (FCS) (Hyclone),
100 units/ml of penicillin (Gibco) 100 units/ml streptomycin (Gibco),
and 2.92mg/ml L-glutamin (Gibco), hereafter referred to as monocyte
culture medium. Isolated monocytes were either left unstimulated in
monocyte culture medium, or were stimulated with 500 μl of LPS or Al
(OH)3 in monocyte culture medium with a ﬁnal concentration of
0.1 μg/ml or 10 μg/ml, for 24 or 48 h respectively, based on the study of
Ulanova et al. [5].
After incubation, culture supernatants were collected and stored at
−80 °C for cytokine analysis. Small aliquots were taken from cell sus-
pensions from each donor per time point for ﬂow cytometry analysis.
For proteome analysis, the cells of at least one well per condition per
time point per donor (three individuals) were washed with PBS, before
adding 500 μl lysis buﬀer (4M Guanidine·HCl in phosphate buﬀer
pH 7.5) (Sigma Aldrich; St Louis; Missouri; United States).
For transcriptome analysis, the cells of at least one well per condi-
tion per time point per donor (5 individuals) were placed in 350 μl of
RLT buﬀer (Qiagen; Venlo; The Netherlands). The samples for proteome
and transcriptome analysis were stored at −80 °C.
2.4. Generation and stimulation of primary Monocyte-Derived Dendritic
Cells (MDDCs)
Monocytes from the peripheral blood of 6 donors, obtained as de-
scribed in the ethics statement, were cultured in a 24-well culture plate
(0.4× 106 cells/ml, 1 ml/well) in DC culture medium, i.e. IMDM
(Gibco) containing 1% FCS, 100 units/ml penicillin, 100 units/ml
streptomycin, 2.92mg/ml L-glutamine (Gibco), 500 units/ml GM-CSF
(Prepotech; Rocky Hill; New Jersey; USA) and 800 units/ml IL-4
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(Sanquin; Amsterdam; The Netherlands) for 6 days. On day 6, the im-
mature MDDCs (iMDDCs) were either left unstimulated, or were sti-
mulated for 48 h with 250 μl of LPS or Al(OH)3 in DC culture medium
containing 250 units/ml GM-CSF, with a ﬁnal concentration of the sti-
mulus of 0.1 μg/ml or 10 μg/ml. After 48 h, supernatant were stored at
−80° for cytokine analysis. The stimulated MDDCs were harvested and
suspended in FACS buﬀer. Aliquots were taken from cell suspensions for
ﬂow cytometric analysis which was used as a quality control for the cell
culture procedure. Flow cytometric analysis of monocytes was used as a
quality control for the cell culture procedure. LPS served as a positive
control and performed as expected, by inducing CD80 expression
(Supplementary S1). Samples were only used for further analysis if the
monocytes were at least 95% pure.
2.5. Culture and stimulation of THP-1 cells
The human monocytic cell line THP-1 (ATCC; Teddington;
Middlesex; U.K.) was used for veriﬁcation experiments of leads iden-
tiﬁed in primary monocytes. THP-1 cells were cultured according to the
supplier's protocol with the addition of 100 units/ml penicillin, 100 μg/
ml streptomycin and 300 μg/ml L-glutamine to the medium, hereafter
referred to as THP-1 culture medium, in culture ﬂasks.
Cells were primed with 300 ng/ml phorbol 12-myristate 13-acetate
(PMA) (Sigma Aldrich) for 24 h, after which the medium was discarded
and new medium without PMA was added. After 24 h in the refreshed
medium, the following stimulations were performed: mock, 50 or
100 μg/ml Al(OH)3 (based on literature [5, 14] and preliminary ex-
periments). Each of these conditions was performed in the presence and
absence of 25 μg/ml glybenclamide (Invivogen). An additional cell
batch was left completely unstimulated and unprimed. Twenty-four and
48 h after stimulation, supernatants of cultures were harvested and used
for an IL-1β ELISA.
2.6. Flow cytometric analysis
For purity analysis, isolated monocytes were stained with PE-con-
jugated anti CD14 clone (H5E2). Cultured monocyte and MDDC cell
suspensions were stained with PE-conjugated anti-CD40 (BD
Biosciences; clone 5C3), APC-conjugated anti-CD80 (BioLegend; clone
2D10), FITC-conjugated anti-CD83 (BD Biosciences; clone HB15e),
Paciﬁc Blue-conjugated anti-CD86 (BioLegend; clone IT2.2), HLA-DR
FITC (Sanquin; clone L243) and ﬁnally with LIVE/DEAD Fixable Aqua
Dead Cell Stain Kit (Invitrogen) for 30min at 4 °C. The cells were wa-
shed in FACS buﬀer and ﬁxed in FACS buﬀer containing 1% paraf-
ormaldehyde (PFA). Data were acquired on a FACS Canto II (BD
Biosciences) and analyzed using FlowJo software (Tree Star) by com-
paring the MFI of the stained control with the MFI of the stained sti-
mulus. The data were corrected for the percentage autoﬂuorescence
determined in veriﬁcation experiments by comparing the unstained
stimulated with the stained stimulated cells for each stimulus.
2.7. mRNA expression analysis
mRNA was isolated from monocyte samples using the RNeasy mini
kit (Qiagen) according to the animal cell spin protocol provided.
Isolated RNA concentrations and purities were determined by the
spectrophotometric analysis of the 260-nm and 280-nm absorbance on
the Nanodrop 2000 (Thermo Fischer). Subsequently, cDNA synthesis
was performed with the RT cDNA synthesis kit (Qiagen) and the RT
preAMP pathway primer mix, innate and adaptive immunity com-
prising primers for 89 functional RNA species and controls, on 12 ng of
RNA per condition (Qiagen). cDNA was subsequently frozen at−20 °C.
qPCR was performed by using the Innate and Adaptive Immune
Responses RT2 Proﬁler PCR Arrays (PAHS 052ZC) (Qiagen)
(Supplementary S2) on a qPCR apparatus (ABI step one plus; Applied
Biosystems; Foster City; California; USA) with a melt curve
determination as a quality control, included in the measurement.
qPCR data were analyzed with the qPCR statistical web software
from Qiagen. Gene expression was normalized to HPRT1 as house-
keeping gene, after which the fold change was calculated according to
the manufacturer's protocol. Fold change-values greater than one in-
dicate an upregulation, in which the fold regulation is equal to the fold
change. Fold change-values less than one indicate a downregulation in
which the fold regulation is the negative inverse of the fold change. For
donor F (with three technical replicates), p-values were calculated
based on a Student's t-test of the replicate values for each gene in the
control group and treatment group. Genes were considered regulated if
p-value<0.05 and a two-fold change in expression occurred. We va-
lidated technical replicate reproducibility with the ﬁrst donor. The
Coeﬃcient of Variation (CV) between technical replicates was 3.5% for
all transcriptome data and all the genes that met the two fold diﬀerence
criterion also had a p-value< 0.05. Therefore, for the other four donors
we used one technical replicate and considered genes regulated if they
met the two-fold diﬀerence criterion. Overall, genes were considered
regulated by Al(OH)3 if they showed a two-fold up- or down-regulation
in at least three out of ﬁve donors, or were regulated in two donors with
a clear trend in at least one other.
LPS served as a control for the time point and for potential artifacts
[25] of the cell isolation with CD14 beads, by determining if LPS-re-
lated genes were indeed increased. It was conﬁrmed that LPS-related
genes were indeed increased after 24 h (Supplementary S3), indicating
that the time point can indeed be used and that artifacts (no induction
of LPS-related genes) might not play a role here.
2.8. Protein isolation
Monocytes were lysed by adding 500 μl 4 M Guanidine·HCl in
100mM phosphate buﬀer (pH=7.5) to the culture plate and incubated
for 2 h at 4 °C. During these 2 h, the cells were subjected to a freeze-
thaw step. The protein concentrations were determined with a BCA
protein assay (Pierce biotechnology; Waltham Massachusetts; USA)
according to the manufacturer's protocol. Lysed cells were stored at
−80 °C in a culture plate.
2.9. Protein digestion
Protein samples from monocytes were diluted 4 times with 100mM
phosphate buﬀer pH 7.5 to reduce the Guanidine·HCl content to 1M
and adjust the pH to 7.5. Proteins were digested at 37 °C with Lys-C
(Roche; Basel; Switzerland) in an enzyme-to-substrate ratio of 1:10 (w/
w). After 4 h, fresh Lys-C was added in a 1:10 (w/w) ratio for an
overnight incubation.
2.10. Protein labeling in monocyte samples
Following the protein digestion, aliquots from the six monocytes
samples per donor (three donors) were taken containing equal protein
amounts and per condition labeled using tandem mass tag labeling 6-
plex (TMT(6), Thermo Fisher). For donor A 25 μg per condition per time
point was labeled, for donor B 50 μg protein per condition per time
point was labeled and for donor C 25 μg protein and 10 μg per condition
was labeled at 24 and 48 h, respectively. Labeling was performed on
Solid Phase Extraction (SPE) columns (Waters; Milford; MA; USA). The
SPE columns were equilibrated as described by the manufacturer and
washed with 100mM phosphate buﬀer pH 7.5. The digested protein
samples were loaded onto 6 separate SPE columns using a vacuum
manifold (Waters) and washed with 100mM phosphate buﬀer pH 7.5.
The TMT-label (0.8 mg per TMT-label) was reconstituted in 41 μl
acetonitrile (AcN) according to the supplier's protocol. The AcN con-
centration was reduced to a maximum of 2.5% (v/v) with 100mM
phosphate buﬀer pH 7.5. The individual TMT labels were loaded onto
the 6 SPE columns, leaving 0.5ml reagent on top of the column for a
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30min incubation, fresh label was added for another 30min of in-
cubation, after which the columns were washed with water containing
0.5% formic acid (FA). The six samples were eluted with 90% AcN
containing 0.5% FA, pooled, dried by centrifugal evaporation and re-
constituted in water containing 0.1% triﬂuoroacetic acid (TFA).
2.11. SCX fractionation
Pooled and labeled monocyte-derived protein samples were puriﬁed
by Strong Cation exchange (SCX) as described previously [26]. The
system comprised a HyperCarb trapping column (200 μm I.D.× 5mm
length, 7 μm particle size) and an SCX column (200 μm I.D.× 11 cm
length PolySULFOETHYL Aspartamide, 5 μm, PolyLC), both made in-
house. The gradient was 12min at 100% solvent A (water + 0.5%
HOAc), after which a linear gradient started to 100% solvent B
(250mM KCl+ 35% AcN+0.5% HOAc in water) in 16.5 min, fol-
lowed by a second linear gradient to 100% solvent C (500mM
KCl+35% AcN+0.5% HOAc in water) in 16.5min at a column ﬂow
rate of 2 μl/min. Twenty-six 4-μL fractions were collected. Fractions
were analyzed for peptide content during fractionation using UV. The
peptide-containing fractions were subjected to nanoscale LC-MS ana-
lysis.
2.12. LC-MS/MS analysis
Peptide separation was performed on a Proxeon Easy-nLC 1000
system (Thermo Scientiﬁc). Peptides were trapped on a double-fritted
trapping column Reprosil C18 (Dr. Maisch; Ammerbuch; Germany;
df= 3 μm, 2 cm length× 100 μm I.D.) and separated at a column
temperature of 40 °C on an analytical column Poroshell 120 EC-C18
(Agilent; df= 2.7 μm, 50 cm length×50 μm I.D.) both packed in
house. Both columns contained a 1-mm length KASIL frit prepared as
described by Meiring et al. [27], to retain the packing bed. The second
KASIL frit, upstream in the trapping column, was made the same way
after ﬂushing the packing bed with helium. Solvent A was 0.1% FA in
MilliQ water and solvent B was 0.1% FA in AcN (Biosolve). The pep-
tides were separated in 143min (10min at 2% B for peptide loading
onto the trapping column, followed by a 118-minute gradient from 2%
to 30% B and 5min at 70% B) in a non-linear optimized gradient [28].
After 128min, the system was kept at 5% B for 15min to equilibrate the
column. The column eﬄuent was electro-sprayed directly into the MS
using a gold-coated fused silica tip with a 5-μm TipID and a spray
voltage of 1.8 kV.
Mass spectrometric data were acquired on a Tribrid-Orbitrap Fusion
(Thermo Fisher Scientiﬁc), where the full scan (MS1) spectra were ac-
quired with a scan range of m/z 350–1500 Da at 120 K resolution
(FWHM) with an Orbitrap readout. The Automatic Gain Control (AGC)
for the MS1 was set to 200,000 and the maximum injection time to
50ms in top speed mode with a duration of 3 s, where precursor ions
with an intensity of> 5000 were selected for fragmentation (MS2).
Charge states between 1 and 7 were selected. MS2 was performed using
Collision-Induced Dissociation (CID) in the linear ion trap with a nor-
malized collision energy of 35%. The AGC for the MS2 was set to 10,000
and the maximum injection time to 35ms. Synchronous-Precursor-
Selection was enabled to include up to 10 MS2 fragment ions. These
ions were further fragmented by Higher energy Collision Dissociation
(HCD) with a normalized collision energy of 50%. TMT reporter ions
were analyzed in the Orbitrap analyzer, with the AGC set to 100,000
and a maximum injection time of 120ms.
Proteomics data were analyzed with Proteome Discoverer 2.1 (PD
2.1) (Thermo Fisher Scientiﬁc) using default settings unless stated
otherwise. Precursor mass tolerance was set to 5 ppm, MS/MS scans
were searched against the human Uniprot database (Nov 2014), con-
taining 23,048 entries, using the Sequest HT search engine with full
enzyme speciﬁcity for Lys-C, with b and y type ions enabled for CID and
HCD data with a fragment mass tolerance of 0.5 Da. The data was
searched with Aspargine deamidation and Methionine oxidation as
dynamic modiﬁcations. TMT(6) was set as a static modiﬁcation on the
Lysine residues and the peptide N-termini. For relative quantitation, the
quantiﬁcation node was used with TMT(6) as deﬁned quantiﬁcation
method and an integration tolerance of 0.2 Da. A decoy database de-
ﬁned in the Percolator node was used to validate and ﬁlter the peptide-
to-spectrum matches with a False Discovery Rate (FDR) of< 5%. Only
medium (FDR<5%) and High (FDR<1%) conﬁdent identiﬁed pro-
teins were used in the further data analysis.
The protein data from the SCX fractions of an individual donor were
combined by PD 2.1 in a consensus report, resulting in one output table
per donor/technical replicate. If multiple entries occurred for the same
protein, based on Uniprot and NCBI data, the ratios given by Proteome
Discoverer were Log2-transformed and averaged for further analysis.
Next, a median correction normalization was performed. For donor C,
three technical replicates of the medium control and Al(OH)3-stimu-
lated culture conditions were measured (their median CV was 10.5% for
the full proteomics data set) and these were combined into a single
average value for this donor to make sure each donor is weighed
equally in further analysis. For donors A and B, one sample per con-
dition was analyzed. Data of three biological replicates (donors) were
compared and proteins that were upregulated or downregulated by 1.5
fold or more in at least two out of three biological replicates were
considered substantially regulated. These regulated proteins were im-
ported in STRING (string.embl.de) [29], to identify enriched pathways
in these regulated protein sets (FDR < 0.05), within Gene Ontology
(GO) biological processes.
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE [30] partner repository
with the dataset identiﬁer PXD008452.
2.13. IL-1β ELISA
IL-1β levels in culture supernatants were determined using the
Human IL-1 beta/IL-1F2 DuoSet ELISA (R&D systems; McKinley;
Minneapolis; USA.). The analysis was performed according to the
manufacturer's protocol and recorded on a Synergy MX (Biotek;
Winooski Vermont; USA).
ELISA data were analyzed with GraphPad Prism®. Signiﬁcance of
diﬀerence was determined using a 2-way ANOVA and a Tukey's mul-
tiple comparison test with an Alpha of 0.05.
3. Results
3.1. Al(OH)3 induces changes in cell surface markers on monocytes but not
on Immature monocyte derived dendritic cells
When immature monocyte-derived dendritic cells (iMDDCs) were
stimulated with Al(OH)3, no signiﬁcant changes in cell surface marker
expression were observed, as determined by ﬂow cytometry, whereas
LPS stimulation resulted in the upregulation of CD40, CD80 and CD83
(Supplementary S4). Based on the limited eﬀect of Al(OH)3 on iMDDCs,
further detailed analyses were only performed using monocytes.
The eﬀect of incubation of monocytes with Al(OH)3 on their cell
surface marker expression was investigated at the level of gene ex-
pression (with targeted transcriptomics) and protein identiﬁcation and
quantiﬁcation. Al(OH)3 stimulation upregulated gene expression of,
CD80, and CD8A in monocytes compared to control cells after 24 h of
stimulation. Gene expression of CD14, a typical monocyte marker that
is lost upon diﬀerentiation into iMDDCs and linked to LPS stimulations
[31], was downregulated in Al(OH)3-stimulated monocytes after 24 h
(Fig. 1), while gene expression was upregulated in LPS-stimulated
monocytes (Supplementary S3, S5). Moreover, at the protein level
(analyzed with quantitative mass spectrometry) CD14 was down-
regulated after 48 h of Al(OH)3 stimulation (Supplementary S6, S7). Al
(OH)3 stimulation of monocytes resulted in an increased protein
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expression of activation markers CD9 and CD71 (TRFC) after 48 h
(Table 2 and Supplementary S6, S7) (please note: these markers were
not analyzed using targeted transcriptomics). These transcriptome and
proteome results conﬁrmed that in an Al(OH)3-stimulated monocyte
population cells became activated and start changing their cell surface
marker phenotype including the loss of CD14 expression.
3.2. Al(OH)3 induces changes in immunogenic genes upon monocyte
stimulation
Targeted transcriptome analysis of monocytes was performed on an
array of 96 genes, comprising innate and adaptive immune system
genes, housekeeping genes and control genes (Supplementary S2). In
total, 89 functional gene-transcripts could be measured, of which 40
genes were found to be upregulated and 5 genes were downregulated
(Table 1 and Fig. 1). Some donor variation was observed since genes
were not always diﬀerentially regulated in all donors. Fig. 1 is most
representative for all donors used.
3.3. Quantitative proteomics reveals up and downregulation of homeostatic
and immunogenic processes after Al(OH)3 stimulation of monocytes
Quantitative proteome analysis of Al(OH)3-stimulated monocytes
resulted in the identiﬁcation of over 4000 unique proteins, of which
3000 proteins could be relatively quantiﬁed. About 200 proteins were
upregulated and about 190 proteins were downregulated in Al(OH)3-
stimulated monocytes compared to unstimulated monocytes
(Supplementary S6–S10). Some of these proteins could be matched to
the transcriptome data, e.g. HLA-A, HLA-E and CD14 (Table 2). Cyto-
kines were not identiﬁed in the lysates. However, several cytokine in-
ducible proteins were detected in the lysates (e.g. Mx1, Mx2 and IFIT3).
These proteins are induced by IFNβ [32–34].
Over-representation analysis of GO terms, revealed the involvement
of various biological processes (Figs. 2 and 3). A comprehensive over-
view of all diﬀerentially regulated proteins and enriched GO terms is
represented in Supplementary S7 and S8–10. Immune processes, like
antigen processing and presentation and innate immune response were over-
represented as well as processes involved in homeostasis like metabolic
processes, localization and transport(Fig. 2). Speciﬁc pathways that were
induced after 24 h were related to localization and copper homeostasis:
speciﬁed proteins related to this process were e.g. copper-transporting
ATPase 2 (ATP7B) and Amyloid-beta A4 (APP). After 48 h of stimula-
tion, additional GO terms were enriched in the upregulated protein sets
as compared to 24 h of stimulation including: intracellular transport
processes (e.g. protein transport, protein localization) and response to stress
(Fig. 3B). Processes related to cell death were also increased after Al
(OH)3 stimulation (programmed cell death). A complete overview can be
found in Supplementary S8–S9.
Within the set of downregulated proteins after 24 h of Al(OH)3 sti-
mulation, no GO terms were over-represented. However, in the data set
representing downregulated proteins after 48 h, over-representation of
various GO terms was identiﬁed i.e. blood coagulation, inﬂammatory
response, regulation of immune system process and response to stress
(Supplementary S10). These data show that Al(OH)3 regulated both
processes involved in homeostasis as well as in the immune response.
3.4. IL-1β production as a consequence of Al(OH)3 stimulation is partially
inﬂammasome dependent
Inﬂammasome-related gene expression was increased in tran-
scriptome analysis after 24 h of Al(OH)3 stimulation, i.e. NOD1 and IL-
1R1, while CASP1 and MyD88 were upregulated in two donors (Fig. 1).
IL-1β ELISA analysis in the culture supernatant of two donors showed a
trend towards increased IL-1β secretion (Supplementary S11). Cytokine
analysis with an IL-β ELISA in THP-1 cells conﬁrmed the upregulation
of IL-1β after 48 h (Fig. 4 and Supplementary S12).
To investigate the involvement of the inﬂammasome in IL-1β pro-
duction upon Al(OH)3 stimulation in more detail, THP-1 cells (a human
monocytic cell line) were diﬀerentiated into macrophages by addition
of PMA and stimulated with 50 μg/ml of Al(OH)3 in the presence and
absence of the inﬂammasome blocker glybenclamide. Measurement of
IL-1β in cell culture supernatants of THP-1 cells revealed that IL-1β
secretion upon Al(OH)3 stimulation decreased in the presence of gly-
benclamide (Fig. 4 and Supplementary S12). A similar trend was ob-
served when tested in primary monocytes: one donor with blocking
(donor A) and one donor without blocking experiment (donor B)
(Supplementary S11). However, this response was less pronounced if
compared to the response in PMA-primed THP-1 cells. The loss of IL-1β
production upon glybenclamide addition provided evidence that the IL-
1β production of Al(OH)3-stimulated monocytic cells is indeed partially
dependent on the activation of the inﬂammasome.
3.5. Al(OH)3 activates the complement system
Our proteomics data of Al(OH)3-stimulated primary monocytes
identiﬁed the altered expression of proteins from all complement
pathways: C4 (lectin pathway), C8 (alternative pathway), and C5aR
(classical pathway) were signiﬁcantly upregulated after 24 h of stimu-
lation (Table 2 and Supplementary S7). In addition, gene expression of
C3 was upregulated and CASP1 was upregulated in two donors
(Table 1).
3.6. Al(OH)3 promotes the production of Th2 and Th1 related cytokines
Notably, in Al(OH)3-stimulated monocytes, the Th1-associated gene
IFNγ [35, 36] was upregulated after 24 h (Fig. 1 and Supplementary
S5). Proteins involved in the response to IFNγ, IFNγR1 and IFI30, were
also upregulated (Supplementary S7). Other cytokine genes increased
after Al(OH)3 stimulation, were IL-2, IL-5, IL-17A, IL-23A and IFNβ
(Fig. 1, Table 1 and Supplementary S5). Interferon-induced protein
with tetratricopeptide repeats 3 (IFIT3) and the interferon-induced
GTP-binding proteins Mx1 and Mx2 were also upregulated (Table 2). In
addition, increased expression of the Th2 polarizing gene IL-4 was ob-
served, after 24 h of stimulation (Table 1 and Fig. 1). However, in the
presence of the Th1-associated gene IFNγ, which was also increased
after 24 h of stimulation.
3.7. Stimulation with Al(OH)3 increases the chemotactic capacity of the
monocytes
Transcriptome data showed that Al(OH)3-stimulated monocytes
regulated mechanisms to attract other immune cells. The gene expres-
sion of CCL2 was upregulated in Al(OH)3-stimulated monocytes
(Table 1); this gene encodes for a molecule involved in monocyte
traﬃcking. Al(OH)3 stimulation also induced the expression of che-
mokine receptors CCR6 and CCR8 (Table 1).
3.8. Al(OH)3 induces upregulation of components of the HLA processing
and presentation pathways in monocytes
The upregulation of HLA class II pathways in monocytes induced by
Al(OH)3 was observed at the level of the proteome. The pathway an-
tigen processing and presentation by HLA class II was enriched in the
upregulated protein data set of Al(OH)3-stimulated monocytes. HLA
class II-related upregulated proteins included Legumain [37–39] and
Cathepsin D, S and L (Table 2 and Supplementary S7) [40]. mRNA
expression of IFNγ was upregulated as was the protein expression of IL-
3R, both synergizing in increasing HLA class II expression [41, 42].
In addition to HLA class II pathway upregulation, induction of HLA
class I-related genes and proteins was observed. Al(OH)3 stimulation of
monocytes increased gene and protein expression of HLA-A and HLA-E,
as well as the gene expression of β2M compared to controls (Table 1 and
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Fig. 1). HLA class I-related proteins were also upregulated upon Al
(OH)3 stimulation i.e. heat shock protein 90 (HSP90) and Minor His-
tocompatibility Complex HM13 (Table 2).
3.9. Al(OH)3 stimulation of monocytes induces IFNβ secretion potentially
by upregulating TLR or NOD like signaling
Al(OH)3 stimulation of monocytes resulted in a signiﬁcantly in-
creased IFNβ gene expression (p < 0.01). Protein expression of pro-
teins downstream of IFNβ: i.e. Mx1, Mx2, and IFIT3 was increased in Al
(OH)3-stimulated monocytes (Supplementary S7), as was the gene ex-
pression of Mx1. This provides evidence that IFNβ indeed has been
secreted, since these proteins would otherwise not have been increased.
These proteins could be induced by IFNβ via STAT1. Indeed, gene ex-
pression of STAT1 was upregulated in Al(OH)3-stimulated monocytes
(Fig. 1 and Supplementary S5). These data conﬁrm the secretion and
consumption of IFNβ.
Indications of IFNβ transcription were also found since the gene
expression of IRF7 a key transcriptional regulator was found to be in-
creased (Fig. 1). IRF3 gene expression was increased in two donors.
Genes involved in the pathways via which IRF7 can mediate the in-
duction of type I interferons were increased, i.e. TICAM1 and IRAK1
while MyD88, and TRAF6 clearly trended towards upregulation
(Table 1 and Supplementary S5) [43]. The protein TBK1 in the IRF7
signaling pathway was identiﬁed at the level of the proteome but was
not increased (Supplementary S6). Upstream of both MyD88/IRAK1
and TICAM/TRAF6, TLR and NOD signaling could be involved, al-
though Al(OH)3 is not a ligand for both TLRs and NOD1. However, Al
(OH)3 induced cell stress and cell death (Supplementary S8 and S9) [13,
16, 19], resulting in the release of DAMPs/endogenous ligands. These
Fig. 1. Gene expression proﬁle of Al(OH)3-stimulated monocytes
after 24 h.
Gene expression was normalized to a housekeeping gene. This ﬁgure
depicts the LOG10(normalized) gene expression proﬁle after 24 h of
Al(OH)3 stimulation (10 μg/ml) compared to the control, of two re-
presentative biological replicas (for an overview of all the altered
genes in three out of ﬁve donors see Table 1). The genes above the
upper dotted line are signiﬁcantly upregulated by at least a factor of 2
as a result of the Al(OH)3 stimulation, while the genes below the
lower dotted lines are downregulated by at least a factor of 2 due to
the Al(OH)3 stimulation.
Table 1
Genes diﬀerentially expressed upon Al(OH)3 (10 μg/ml) stimulation of monocytes.
Pattern recognition receptors
(PPRs) and signaling
Cytokines and
chemokines
Cytokine and
chemokine receptors
Surface
markers
Transcription factors Complement system Antigen
presentation
Others
NOD12 CCL22 CCR62 CD8A2 FoxP32 C32 β2M2 ACTβ2
TLR22 CSF22 CCR82 CD802 GATA32 CASP12 HLA-A2 CD40LG2
TLR32 IL-22 CXCR32 CD41 IRF32 HLA-E2 CRP2
MYD882 IL-42 IL-1R12 CD141 IRF72 MPO2
IRAK12 IL-5 TBX211 MX12
TICAM12 IL-17A2 RAG12
DDX582 IL-23A STAT12
IFNαR12 STAT32
IFNβ12 STAT62
IFNγ2 TYK22
TNF2 TRAF62
IL-1β1 MAPK12
IL-181 MAPK82
RORC2
LY962
LYZ1
NLRP31
Italic genes: genes that are upregulated/downregulated in 2 donors and a trend towards upregulation in at least one additional donor.
1 Annotated genes that are downregulated by at least a factor of 2 in at least 3 donors.
2 Annotated genes that are upregulated by at least factor of 2 in at least 3 donors.
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endogenous ligands can bind various receptors leading to the secretion
of type I interferons. Gene expression of a subset of these DAMP sensors
was identiﬁed in this data set, speciﬁcally DDX58, (no further pathway
evidence identiﬁed) TLR2 (upregulated in two donors but down-
regulated in one), TLR3 (upregulated in four donors) and NOD1 (in two
donors tending towards upregulation in at least one more) (Fig. 1).
TLR3 can be activated by endogenous mRNA [44–46] resulting in the
secretion of type I interferons, via the induction of TICAM1, TRAF6,
TBK1 and IRF7 [44, 45, 47]. TLR2 (upregulated in two donors and
downregulated in one donor) can be induced by endogenous ligands
and induce the secretion of type I interferons via the pathway described
by Dietrich et al. [48]. NOD1 can also be induced by endogenous li-
gands and results in the formation of type I interferons [49, 50]. These
data indicate the TLR signaling and NOD1 signaling could be involved
in the induction of type I interferons by DAMP sensing.
Although involvement of other DNA sensors cannot be excluded,
hypothetical Al(OH)3-induced pathways resulting in the release of type
I interferons, based on the data described and the literature are depicted
in Fig. 5.
4. Discussion
A comprehensive analysis of the eﬀects of Al(OH)3 on monocytes
revealed two novel cellular processes to be involved in the adjuvant
action of Al(OH)3: ﬁrst, IFNβ secretion via NOD1 or TLR signaling and
second, the upregulation of antigen processing and presentation via
HLA class I-related proteins, potentially leading to more antigen pro-
cessing and presentation when an antigen is present. Together with a
deeper elucidation of known Al(OH)3-aﬀected mechanisms, these novel
processes emphasize that Al(OH)3-stimulated monocytes prepare for a
pro-inﬂammatory function and antigen presentation in the immune
response [22–24].
Known mechanisms of Al(OH)3 (as reviewed by He et al. [12]) were
elucidated in more detail: inﬂammasome activation, complement acti-
vation, cytokine induction, monocyte activation and diﬀerentiation and
induced HLA-class II activation possibly due to increased IFNγ gene
expression. It is noteworthy that IFNγ gene expression is induced as a
result of Al(OH)3 stimulation. As the gene targets were measured at
mRNA level and the proteins induced by these measured genes were
determined to be increased by proteomics-enabled mass spectrometry,
it can be stated that the genes actually have been translated into
Table 2
Selection of proteins and their fold changes after 24 and 48 h of Al(OH)3 (10 μg/ml)
stimulation compared to control in primary monocytes.
Accession number Protein Fold changes after 24 h Fold changes after 48 h
P05534 HLA-A 1.05 15.53
P13747 HLA-E 2.65 15.01
Q8TCT9 HM13 2.11 4.01
Q99538 LGMN 2.20 3.08
P07339 CTSD 2.43 3.35
P07711 CTSL 7.04 6.85
P25774 CTSS 1.22 1.71
O60911 CSTV 2.53 2.39
P21926 CD9 1.57 2.82
P08571 CD14 0.67 0.20
P02786 TFRC 1.47 3.32
P20591 MX1 1.36 1.62
P20592 MX2 1.26 1.72
P13284 IFI30 2.31 1.49
O14879 IFIT3 1.62 2.53
P26951 IL3RA 3.37 90.58
P15260 IFNgR1 2.02 3.37
Q9UHD2 TBK1 0.92 0.99
P0C0L4 C4 1.86 1.74
P21730 C5aR1 1.50 1.97
P07357 C8a 2.64 1.77
P07358 C8b 6.86 0.93
(caption on next page)
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proteins and subsequently induced downstream pathways; e.g. IFNβ
induction was measured at the gene expression level and Mx1, Mx2 and
IFIT3 were measured at protein level (Table 2 and Supplementary S7),
these proteins are speciﬁcally induced by type I interferons [32, 33]. By
combining the transcriptome and proteome analysis, pathways can be
identiﬁed in more detail, despite the sometimes relative low coherence
between protein and gene expression with respect to the same Uniprot
entry. This might be related to the limited set of genes investigated, due
to diﬀerences in kinetics or due to the fact that secreted proteins
probably have not been identiﬁed in the cell lysates. By combining
these techniques it is possible to analyze activated pathways, based on
the identiﬁcation of selected cytokines and downstream proteins.
One of the novel processes identiﬁed is the induction of IFNβ se-
cretion resulting from Al(OH)3 stimulation, most likely due to TLR2,
TLR3 NOD like or other DAMP signaling. IFNβ gene expression was
increased in Al(OH)3-stimulated monocytes. Downstream of IFNβ,
various proteins were induced: e.g. Mx1, Mx2 and IFIT3 were increased
in Al(OH)3-stimulated monocytes. These proteins can be induced by
IFNβ via STAT1. Indeed, gene expression of STAT1 was upregulated in
Al(OH)3-stimulated monocytes (Fig. 1). Upstream of IFNβ, IRF7 gene
expression was increased as was the expression of IRF3 in two biolo-
gical replicates. These inducers of type I interferon secretion can be
activated via various pathways. Multiple of these inducers were iden-
tiﬁed and upregulated at the level of gene expression: TICAM1, TRAF6,
MyD88 and IRAK1. Upstream of these molecules, TLR signaling can be
involved. In this data set, TLR3 was upregulated at the level of gene
expression. TLR2 was upregulated in two donors (Table 1). Al(OH)3 is
not a direct ligand for either of these pathways, however Al(OH)3
causes the release of endogenous ligands by inducing cell death [13, 16,
19]. Indeed, markers of cell stress and cell death were identiﬁed in the
protein dataset in this study (Fig. 3A, B, Supplementary S6–S9). These
endogenous ligands can activate TLR3 and downstream signaling
[44–46] and TLR2 directly or indirectly via TLR3 [51–54]. The acti-
vation of TLR3 results in recruitment of TICAM1 followed by the acti-
vation of IRF3/IRF7 leading to type I Interferon transcription. The ac-
tivation of TLR2 can result in the formation of a complex with MyD88
and the internalization of this complex towards the endolysosome
where this complex binds IRAK1. Subsequently, IRAK1 phosphorylates
IRF3/IRF7, resulting in the transcription and secretion of type I inter-
ferons [48]. Many of the genes involved in these pathways were found
to be upregulated as can be seen in Fig. 5. Since TLR2 was upregulated
in two donors but downregulated in one donor, the pathway via TLR3 is
Fig. 2. Heatmap of all Al(OH)3-regulated proteins in monocytes.
The heatmap represents the median of all upregulated (red) and downregulated (green)
proteins from 3 biological replicates on a LOG2 scale after 24 and 48 h of Al(OH)3 sti-
mulation (10 μg/ml). Regulated proteins were at least altered by a factor 1.5 compared to
the control in at least two out of three biological replicates. Enrichment analysis of GO
biological processes was performed on the regulated proteins; depicted processes have
FDRs< 0.05. The proteins were clustered by GO term as described in Supplementary S7.
Fig. 3. Enriched GO biological process terms in the upre-
gulated protein set after 24 and 48 h of Al(OH)3stimulation
of monocytes.
The GO terms are biological processes that are signiﬁcantly
overexpressed (p-values< 0.1) in the upregulated protein
data set after 24 h of Al(OH)3 stimulation (10 μg/ml) (3A)
and 48 h (3B) from three biological replicates. The bars
depict the percentage of upregulated proteins out of the
total proteins in this GO term. The numbers display the
ratios between upregulated proteins and total proteins in
this GO term and the numbers between brackets are refer-
ring to the speciﬁed GO term.
Fig. 4. IL-β levels in supernatants of THP-1 cell cultures upon Al(OH)3 stimulation of
THP-1 cells.
PMA-treated THP-1 cells were stimulated with 50 μg/ml Al(OH)3 with or without the
inﬂammasome blocker glybenclamide. IL-1β levels, measured after 48 h of stimulation,
were compared to non-blocked Al(OH)3-stimulated cells. Data are represented as the
mean and the standard deviation of three independent experiments (biological replicates,
each, with at least two technical replicates p-values< 0.05 are depicted as ⁎ and p-va-
lues<0.005 are depicted as ⁎⁎⁎). Medium represents control cells, medium+ represents
medium with the PMA prime and 50 μg Al(OH)3 represents the PMA-primed, Al(OH)3-
stimulated group.
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more likely to be involved in type I Interferon induction than the
pathway via TLR2.
Detection of cytosolic DNA or other DAMPs is another possible
cause of IFNβ induction [16]. Two of those DAMP sensors are NOD1
and DDX58 [19, 49, 50]. NOD1 gene expression was found to be in-
creased. Activation of NOD1 results in a similar pathway as the TLR2/
TLR3 signaling pathway (Fig. 7). DDX58 gene expression was upregu-
lated in this data set, however, no further evidence of the activation of
this pathway was identiﬁed. This is in agreement with the data from
Marichal et al. describing that the DDX58-STING pathway might not be
involved in the adjuvant eﬀect of Al(OH)3 [12, 19]. However, based on
this data this pathway cannot be excluded. TLR8 and TLR9 are other
potential DAMP sensors. Protein expression of TLR8 was down-
regulated and the gene expression of TLR8 and TLR9 was not increased
in Al(OH)3-stimulated monocytes, probably excluding TLR8 and TLR9
from a role in the adjuvant eﬀect of Al(OH)3. These results show that Al
(OH)3-induced DAMPS could be involved in the formation of IFNβ,
most likely by activation TLR2 and/or TLR3 and by NOD1 signaling
pathways, since many genes and proteins were upregulated in Al(OH)3-
stimulated cells that belong to these pathways. Other potential sensors
for DNA in the cytoplasm signaling via the Caspase recruitment and
activation domain (CARD) were not identiﬁed in the proteomics data,
but cannot be excluded from being involved in Interferon secretion. It
has been described that TLR signaling is not involved in the Ab response
in Al(OH)3-stimulated DCs [12, 15], however, a potential role for TLR
signaling in the induction of interferons has been described earlier [16],
as is the interaction with the inﬂammasome [55–57]. This data indicate
that TLR signaling can be involved in the adjuvant eﬀect of Al(OH)3.
The induction and secretion of type I interferons can be related to
processes described above, amongst others: diﬀerentiation away from a
monocytic cell type, chemotaxis via the induction of CCL2, the increase
of HLA class I and class II, activate complement and induce or inhibit
the secretion of various cytokines as described previously [58–60]. This
implies that type I interferons are crucial mediators of the innate im-
mune response induced by Al(OH)3. In addition, secretion of type I
interferons (IFNβ) after Al(OH)3 stimulation, might have several eﬀects
if the eﬀects induce innate memory. Innate memory is the phenomenon
of innate immune cells, like NK cells and macrophages, that are per-
manently changed after stimulation. Interferons play a role in inducing
this innate memory [61]. First, type I interferons induced via TLR sig-
naling are essential in the host response to virus. Second, they prime NK
cells and macrophages [62, 63], of major importance for an early
clearance of infections and the maturation of Th1 cells, which can be
needed to induce memory [64, 65]. Third, type I interferons are es-
sential for the survival of both CD4+ and CD8+ T cells [63], but most
relevant for the immune response upon vaccination is the stimulation of
local B cells by type I Interferons [66]. Therefore, IFNβ secretion can be
important in the adjuvant eﬀect of Al(OH)3.
The other novel mechanism identiﬁed in this study is the increased
activation of the antigen presentation pathway via HLA class I. It was
recently described that activated monocytes have a fundamental role in
antigen presentation to T cells in the lymph nodes and that antigen
presenting monocytes can in fact cross present to HLA class I [24]. This
study showed an upregulation of HLA class I molecules HLA-A and
HLA-E, on both the level of gene expression and protein expression.
Moreover, an increased protein expression of HM13 and an increased
gene expression of β2M and IFNγ was observed, all related to antigen
presentation via HLA class I [41, 67]. These results show that Al(OH)3
increased the expression of HLA class I molecules on monocytes which
leads to enhanced antigen presentation. Although Al(OH)3 is capable of
activating CD8+ T cells, these T cells will likely not develop into mature
cytotoxic T cells but rather into CD8+ memory T cells [8, 13, 68–70].
Nevertheless, Al(OH)3 is mainly considered an inducer of CD4+ T cells
[5, 13, 71]. HLA-E plays a role in the stimulation of NK cells. NK cells
speciﬁcally recognize the HLA-E-peptide complex, which can inhibit
and excite the response, depending if the peptide is self or foreign, such
as a viral peptide [72, 73]. This is a useful process in inducing the
immune response or preventing autoimmunity.
Besides increased expression of HLA class I molecules, an increased
expression of components of the HLA class II pathway after Al(OH)3
stimulation was observed, like Legumain, Cathepsins S, L, B and D.
There is conﬂicting literature regarding the eﬀect of Al(OH)3 on HLA
class II expression [5, 6, 74]. The increased expression of HLA class II
molecules by Al(OH)3 might be due to IFNγ signaling [41]. Indeed, in
our study mRNA of IFNγ was increased. Moreover, protein expression of
IFNγR1, and IFI30, a downstream molecule of the IFNγ signaling
pathway, was increased. IFNγ-induced increase of HLA class II can be
synergized by IL-3 and the IL-3R receptor, of which protein expression
was increased [42]. The detection of several Cathepsins (S, L, D) and
IFI30, which is required for antigen presentation via HLA class II,
supports the hypothesis that Al(OH)3 increases HLA class II antigen
presentation by monocytes and that the increase of HLA class II mole-
cules in monocytes might be due to the induction of IFNγ and sub-
sequent signaling.
Fig. 5. Hypothetical pathways resulting in IFNβ secretion, potentially
via TLR2/TLR3 and NOD1 pathways that become activated upon Al
(OH)3 stimulation of monocytes.
TLR2 and TLR3 can be activated by DAMPS, after which two path-
ways can be activated: one leading to the formation of NFκB and the
second pathway leading to the formation of IFNβ and downstream
proteins. NOD1 activation leads to the secretion of IFNβ. Genes are
annotated in circles, proteins are annotated in boxes.
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As described previously, Al(OH)3 induced the downregulation of
CD14 [6]. This ﬁnding indicates that Al(OH)3-stimulated monocytes are
starting to diﬀerentiate away from a monocytic cell type and that the
cells become activated, which was conﬁrmed by the increase of acti-
vation marker CD71 for monocytes. For the response to Al(OH)3 it was
expected that the response would be well measureable after 24 h, since
the responses towards LPS could still be detected after 24 h; this time
point was also based on the study of Ulanova et al. [75–77].
Induction of cytokines by an adjuvant is important in steering the
immune response. Al(OH)3 is described as an adjuvant that primes for a
Th2 response by inducing IL-4 [5]. Indeed, our results show production
of the Th2 polarizing cytokine IL-4 by monocytes upon Al(OH)3 sti-
mulation. Presumably, the IL-4 response is dominant and may inhibit
Th1 polarization In response to Al(OH)3. However, innate IFNγ is as-
sociated with a Th1 response [36, 69]. A more Th1-related response to
Al(OH)3 was observed in multiple studies related to Al(OH)3 [69]. IFNγ
was secreted in IL-4 knockout mice [9] resulting in a more Th1-related
response. IFNγ has more functions then solely being a Th1-associated
cytokine. Thus, the polarization towards a Th2 type response occurs
upon Al(OH)3 stimulation despite the IFNγ produced.
One of the known mechanisms in the adjuvant activity of Al(OH)3
besides preparing the innate immune system for antigen presentation
and T cell activation, is the activation of the inﬂammasome leading to
the secretion of IL-1β. This was conﬁrmed in primary monocytes, by the
increased gene expression of NOD1, IL1R1 and a trend in CASP1 and
MyD88. In addition, a trend towards increased IL-1β secretion was
observed in primary monocytes (2 donors) as was the reduction of IL-1β
secretion when the inﬂammasome was blocked (1 donor). In PMA-
primed THP-1 cells, an inﬂammasome inhibition experiment was per-
formed that resulted in a reduced IL-1β secretion. PMA-primed THP-1
cells were used to further elucidate the inﬂammasome dependent origin
of IL-β. THP-1 cells were used because, the levels of IL-1β detected in
primary monocytes were low and THP-1 cells are a useful model since
PMA priming causes the production of pro IL-1β and subsequent ex-
posure to Al(OH)3 can increase actual IL-1β, mimicking the two step
activation required for inﬂammasome induction [78–80]. THP-1 cells
are immortalized cells that diﬀer in sensitivity form primary monocytes
in response to stimuli such as LPS, due to diﬀerences in the cell surface
marker expression of [81, 82]. However, the conﬁrmation of the role of
the inﬂammasome pathway in the IL-1β secretion in THP-1 cells sug-
gests a similar involvement of the inﬂammasome in primary monocytes,
since leads were also found in the primary monocyte data.
Complement activation is another mechanism described to be in-
duced by Al(OH)3 [18], either by Al(OH)3 directly or by dying cells;
genes and proteins related to the classical, alternative and lectin path-
ways were upregulated in this dataset [18]. In our study, transcriptome
data revealed the upregulation of C3 showing the initiation of the
complement cascade, while at the level of the proteome C4, C5A and C8
were upregulated, representing the diﬀerent complement pathways.
These results show that combined use of transcriptomics and pro-
teomics is valuable. At the transcriptome level, the initiation of the
complement cascade was observed while with the proteome data the
speciﬁc pathways were determined. The activation of complement
pathways can be useful for bacterial lysis, and clearing apoptotic cells,
which could prevent autoimmunity [83].
This study demonstrates that the response to Al(OH)3 is very com-
plex (Fig. 6), but also indicates that there might be considerable dif-
ferences between in vivo and in vitro models. This might be caused by
the use of a single cell type in vitro versus the availability of an intact,
coherent immune system in vivo. Also, the species diﬀerence between
cells from humans and mice might play a role. In mouse models, it was
observed that Al(OH)3 skews to a Th2 response [84]. In this study we
indeed observed a polarization of the immune response towards a Th2
response, but in the presence of the Th1-associated gene IFNγ.
Fig. 6. Overview of the kinetics from the monocyte response towards Al(OH)3 in combination with the analytical tool used.
The green blocks represent cytokines and related proteins. The light blue blocks represent the surface markers. The purple blocks represent the HLA-class I and class II antigen
presentation pathways. The dark blue blocks represent the inﬂammasome activation. The orange blocks represent complement activation.
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5. Conclusion
The immune response is a complex interplay of many molecules,
residing in diﬀerent tissues and cellular compartments. Hence, our
model system, utilizing primary monocytes, does not include the co-
herent adaptive immune response upon Al(OH)3 stimulus. Moreover,
the present study did not include a particular antigen adsorbed to Al
(OH)3 which might also contribute to the innate immune response in-
duced by Al(OH)3.
Our systems biology-based approach revealed a detailed overview
of the molecular mechanisms of Al(OH)3 as an adjuvant for monocyte
responsiveness (Fig. 6). Most important, the monocyte response to Al
(OH)3 is broad as illustrated by the induction of Th2-polarizing factors,
the induction of type I and type II interferons and the upregulation of
both HLA class I and HLA class II pathways, even in the absence of
antigens. In this study, two new modes of action of Al(OH)3 were elu-
cidated, i.e. the upregulation of IFNγ in relation to HLA regulation and
antigen presentation and the IFNβ secretion possibly as a result of
TLR2, TLR3 or NOD1 activation. Finally, by combining complementary
techniques, e.g. functional assays, transcriptome data and proteome
data, it was possible to create a detailed overview of cellular processes
in response to Al(OH)3, which are important in the adjuvant eﬀect of Al
(OH)3.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jprot.2017.12.021.
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